BiotechTube

Sevoflurane + propofol + remifentanil

ApprovedCompleted
2 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Intra-abdominal and Intrapelvic Surgery

Conditions

Intra-abdominal and Intrapelvic Surgery

Trial Timeline

Mar 1, 2013 → Apr 1, 2019

NCT ID
NCT01809041

About Sevoflurane + propofol + remifentanil

Sevoflurane + propofol + remifentanil is a approved stage product being developed by Baxter for Intra-abdominal and Intrapelvic Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT01809041. Target conditions include Intra-abdominal and Intrapelvic Surgery.

What happened to similar drugs?

2 of 15 similar drugs in Intra-abdominal and Intrapelvic Surgery were approved

Approved (2) Terminated (0) Active (13)
✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
✅Tigecycline + Imipenem/cilastatinPfizerApproved
🔄Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
🔄MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mgMerckPhase 3
🔄CXA-201 and metronidazole + MeropenemMerckPhase 3
🔄Imipenem+Cilastatin/RelebactamMerckPhase 3
🔄Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 WeeksMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01809041ApprovedCompleted

Competing Products

20 competing products in Intra-abdominal and Intrapelvic Surgery

See all competitors
ProductCompanyStageHype Score
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactamMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
40
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mgMerckPhase 3
40
CXA-201 and metronidazole + MeropenemMerckPhase 3
40
Imipenem+Cilastatin/RelebactamMerckPhase 3
40
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
35
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 WeeksMerckPhase 3
40
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
40
LYS228 + Standard of care therapyNovartisPhase 2
27
Ceftazidime-avibactam + metronidazole + MeropenemPfizerPhase 3
40
Tigecycline + Imipenem/cilastatinPfizerApproved
43
ceftazidime/NXL104 + metronidazole + meropenemPfizerPhase 2
35
ATM-AVI + MetronidazolePfizerPhase 2
35
Tigecycline (Tygacil)PfizerPre-clinical
26
Ceftazidime -avibactam + Meropenem + MetronidazolePfizerPhase 2
35
PF-06947386 + MetronidazolePfizerPhase 3
40
TigecyclinePfizerPre-clinical
26
CAZ-AVI + Metronidazole + MeropenemPfizerPhase 3
40